47258 Federal Register / Vol. 74, No. 177 / Tuesday, September 15, 2009 / Notices 

Applications: 

• Investigation of food borne illness. 

• Monitoring of seafood for 

contamination. 

• Detection of food poisons. 

Inventor: Sherwood Hall (FDA). 

Relevant Publication: EJ Schantz et al. 

Paralytic shellfish poison. VI. A 

procedure for the isolation and 

purification of the poison from toxic 

clam and mussel tissues. J Am Chem 

Soc. 1957 Oct;79(19):5230–5235, doi: 

10.1021/ja01576a044. 

Patent Status: HHS Reference No. E– 

278–2009/0—Research Tool. Patent 

protection is not being pursued for this 

technology. 

Licensing Status: Available for 

licensing. 

Licensing Contact: Michael A. 

Shmilovich, Esq.; 301–435–5019; 

shmilovm@mail.nih.gov. 

Identification of Recent HIV–I Infection 

by Genotypic Analysis for Treatment 

Strategy 

Description of Technology: This 

invention describes a bioinformatics 

algorithm capable of distinguishing 

between recently infected and 

chronically infected HIV–I patients 

based on the genetic diversity of HIV 

pro-pol sequences. Directly after 

infection with HIV–I, genetic diversity 

is extremely low. Previously, single 

genome sequencing was used to 

demonstrate that HIV–I genetic diversity 

accumulates after infection in a linear 

and predictable fashion during the first 

8–10 months of infection (Kearney et 

al., 2009). Using single genome 

sequencing, it is possible to determine 

whether a person had been infected 

with HIV–1 in the recent past. Single 

genome sequencing is, however, a 

research technique that is relatively 

labor intensive and somewhat 

expensive, making it less feasible for 

routine use. The invention improves on 

this analysis in both ease and cost, and 

is capable of estimating genetic diversity 

using a population-based sequence that 

is obtained by routine, commercially 

available genotyping through the 

determination of genotype sequence 

ambiguity, which resulted in both 

sensitive and specific identification of 

acute versus chronic infection. The 

algorithm is also capable of 

simultaneously determining drug 

resistance profiles, further representing 

significant improvement over current 

antibody-based methods. Since recent 

data have shown that patients in the 

primary infection stage are estimated to 

be 26 times more infective than patients 

in the chronic stage of infection 

(Hollingsworth et al., 2008), and 

epidemiological models of immediate 

antiretroviral therapy (ART) predict a 

shift from the endemic phase to the 

elimination phase within five years 

(Granich et al., 2009), this invention 

represents a potentially valuable 

diagnostic tool for clinicians as well as 

an improvement over the current 

antibody-based methods of 

epidemiological research for 

determining HIV incidence. 

Applications: 

• HIV Diagnostics capable of 

distinguishing between a recent HIV 

infection and a chronic one. This feature 

will assist clinicians in the design of 

HIV treatment regimen and strategy. 

• Analysis and prediction of patient’s 

HIV drug resistance. Facilitating 

devising a treatment strategy. 

• Epidemiological application due to 

ability of the test to report HIV 

incidence. 

Advantages: The method offers 

important public health benefits with 

regards to HIV/AIDS as elaborated 

below: 

• The method adds important value 

to conventional HIV genotyping and 

enhances the diagnostic usefulness of 

genotyping. 

• The method offers an inexpensive 

and convenient way to distinguish 

recently infected from chronically 

infected subjects and thus provides 

important information regarding HIV 

drug management. 

• The method can, simultaneously 

with the above, provide information 

regarding drug resistance mutations. 

• The method is based on 

commercially available HIV–1 genotype 

sequence information and thus offers 

simplicity and convenience. 

• The method can provide important 

and useful epidemiological information. 

Market: A favorable market potential 

for the method exists, and it may in the 

future be routinely used in every 

clinical laboratory that provides 

genotyping services and by 

manufacturers and laboratories that 

provide tests for drug resistance 

patterns. 

Development Status: Early stage. 

Inventors: Frank Maldarelli et al. 

(NCI). 

Patent Status: HHS Reference No. E– 

238–2009/0—Research Tool. Patent 

protection is not being pursued for this 

technology. 

Licensing Status: Available for 

licensing. 

Licensing Contacts: Uri Reichman, 

PhD, MBA, 301–435–4616, 

UR7a@nih.gov; John Stansberry, PhD, 

301–435–5236, js852e@nih.gov. 

Collaborative Research Opportunity: 

The NCI HIV Drug Resistance Program, 

Host Virus Interaction Branch, is 

seeking statements of capability or 

interest from parties interested in 

collaborative research to further 

develop, evaluate, or commercialize this 

technology. Please contact John D. 

Hewes, PhD at 301–435–3121 or 

hewesj@mail.nih.gov for more 

information. 

Dated: September 9, 2009. 

Richard U. Rodriguez, 

Director, Division of Technology Development 

and Transfer, Office of Technology Transfer, 

National Institutes of Health. 

[FR Doc. E9–22223 Filed 9–14–09; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Center for Scientific Review; Notice of 

Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel Tachycardias 

and Arrhythmias. 

Date: September 22, 2009. 

Time: 11 a.m. to 1 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892. 

(Telephone Conference Call). 

Contact Person: Olga A. Tjurmina, PhD, 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 4138, 

MSC 7814 Bethesda, MD 20892. (301) 451– 

1375. ot3d@nih.gov. 

This notice is being published less than 15 

days prior to the meeting due to the timing 

limitations imposed by the review and 

funding cycle. 


sroberts on DSKD5P82C1PROD with NOTICESEN15SE09.032</GPH>
Federal Register / Vol. 74, No. 177 / Tuesday, September 15, 2009 / Notices 47259 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel Nucleosome 

Structure—Function. 

Date: September 30–October 1, 2009. 

Time: 8 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Mark Hopkins Hotel, One Nob Hill, 

San Francisco, CA 94108. 

Contact Person: Richard A. Currie, PhD, 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 1108, 

MSC 7890 Bethesda, MD 20892. (301) 435– 

1219. currieri@csr.nih.gov. 

Name of Committee: Genes, Genomes, and 

Genetics Integrated Review Group Ethical, 

Legal, and Social Implications of Human 

Genetics Study Section. 

Date: September 30, 2009. 

Time: 11 a.m. to 4 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892. 

(Telephone Conference Call). 

Contact Person: Cheryl M. Corsaro, PhD, 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 2204, 

MSC 7890 Bethesda, MD 20892. (301) 435– 

1045. corsaroc@csr.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.306, Comparative Medicine; 

93.333, Clinical Research, 93.306, 93.333, 

93.337, 93.393–93.396, 93.837–93.844, 

93.846–93.878, 93.892, 93.893, National 

Institutes of Health, HHS) 

Dated: September 3, 2009. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. E9–22006 Filed 9–14–09; 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Diabetes and 

Digestive and Kidney Diseases; Notice 

of Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the following meetings. 

The meetings will be open to the 

public as indicated below, with 

attendance limited to space available. 

Individuals who plan to attend and 

need special assistance, such as sign 

language interpretation or other 

reasonable accommodations, should 

notify the Contact Person listed below 

in advance of the meeting. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Diabetes and Digestive and Kidney Diseases 

Initial Review Group; Digestive Diseases and 

Nutrition C Subcommittee. 

Date: October 7–8, 2009. 

Open: October 7, 2009, 8 a.m. to 8:30 a.m. 

Agenda: To review procedures and discuss 

policy. 

Place: The Fairmont Washington, DC, 2401 

M Street, NW., Washington, DC 20037. 

Closed: October 7, 2009, 8:30 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: The Fairmont Washington, DC, 2401 

M Street, NW., Washington, DC 20037. 

Closed: October 8, 2009, 8 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: The Fairmont Washington, DC, 2401 

M Street, NW., Washington, DC 20037. 

Contact Person: Dan E. Matsumoto, PhD, 

Scientific Review Officer, Review Branch, 

DEA, NIDDK, National Institutes Of Health, 

Room 749, 6707 Democracy Boulevard, 

Bethesda, MD 20892–5452, (301) 594–8894, 

matsumotod@extra.niddk.nih.gov. 

Name of Committee: National Institute of 

Diabetes and Digestive and Kidney Diseases 

Initial Review Group; Diabetes, 

Endocrinology and Metabolic Diseases B 

Subcommittee. 

Date: October 13–15, 2009. 

Open: October 13, 2009, 5 p.m. to 5:30 p.m. 

Agenda: To review procedures and discuss 

policy. 

Place: Hyatt Regency Bethesda, One 

Bethesda Metro Center, 7400 Wisconsin 

Avenue, Bethesda, MD 20814. 

Closed: October 13, 2009, 5:30 p.m. to 9 

p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Hyatt Regency Bethesda, One 

Bethesda Metro Center, 7400 Wisconsin 

Avenue, Bethesda, MD 20814. 

Closed: October 14, 2009, 8 p.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Hyatt Regency Bethesda, One 

Bethesda Metro Center, 7400 Wisconsin 

Avenue, Bethesda, MD 20814. 

Closed: October 15, 2009, 8 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Hyatt Regency Bethesda, One 

Bethesda Metro Center, 7400 Wisconsin 

Avenue, Bethesda, MD 20814. 

Contact Person: John F. Connaughton, PhD, 

Chief, Chartered Committees Section, Review 

Branch, DEA, NIDDK, National Institutes Of 

Health, Room 753, 6707 Democracy 

Boulevard, Bethesda, MD 20892–5452, (301) 

594–7797, 

connaughtonj@extra.niddk.nih.gov. 

Name of Committee: National Institute of 

Diabetes and Digestive and Kidney Diseases 

Initial Review Group; Kidney, Urologic and 

Hematologic Diseases D Subcommittee. 

Date: October 21–22, 2009. 

Open: October 21, 2009, 8 a.m. to 8:30 a.m. 

Agenda: To review procedures and discuss 

policy. 

Place: Residence Inn Bethesda, 7335 

Wisconsin Avenue, Bethesda, MD 20814. 

Closed: October 21, 2009, 8:30 a.m. to 5 

p.m. 

Agenda: To review and evaluate grant 

applications 

Place: Residence Inn Bethesda, 7335 

Wisconsin Avenue, Bethesda, MD 20814. 

Closed: October 22, 2009, 8 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Residence Inn Bethesda, 7335 

Wisconsin Avenue, Bethesda, MD 20814. 

Contact Person: Barbara A. Woynarowska, 

PhD, Scientific Review Administrator, 

Review Branch, DEA, NIDDK, National 

Institutes Of Health, Room 754, 6707 

Democracy Boulevard, Bethesda, MD 20892– 

5452, (301) 402–7172, 

woynarowskab@niddk.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.847, Diabetes, 

Endocrinology and Metabolic Research; 

93.848, Digestive Diseases and Nutrition 

Research; 93.849, Kidney Diseases, Urology 

and Hematology Research, National Institutes 

of Health, HHS) 

Dated: September 4, 2009. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. E9–22007 Filed 9–14–09; 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute on Deafness and 

Other Communication Disorders; 

Notice of Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of a meeting of the Board 

of Scientific Counselors, NIDCD. 

The meeting will be open to the 

public as indicated below, with 

attendance limited to space available. 

Individuals who plan to attend and 

need special assistance, such as sign 

language interpretation or other 

reasonable accommodations, should 

notify the Contact Person listed below 

in advance of the meeting. 

The meeting will be closed to the 

public as indicated below in accordance 

with the provisions set forth in section 

552b(c)(6), Title 5 U.S.C., as amended 

for the review, discussion, and 

evaluation of individual intramural 

programs and projects conducted by the 

National Institute on Deafness and 


sroberts on DSKD5P82C1PROD with NOTICES